SMT201300060B - Composti diammidici aventi attivita' di antagonista al recettore muscarinico e di agonista al recettore beta 2 adrenergico - Google Patents

Composti diammidici aventi attivita' di antagonista al recettore muscarinico e di agonista al recettore beta 2 adrenergico

Info

Publication number: SMT201300060B
Authority: SM; San Marino
Prior art keywords: diamid; beta; compounds; antagonist activity; receptor antagonist
Prior art date: 2009-04-23

Application number

SM201300060T

Other languages

English (en)

Inventor

Eric L Stangeland

Adam Hughes

Daniel Byun

Yan Chen

Melissa Fleury

John R Jacobsen

Richard D Wilson

Rose Yen

Original Assignee

Theravance Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-23

Filing date

2013-06-07

Publication date

2013-07-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42272140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201300060(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-06-07 Application filed by Theravance Inc filed Critical Theravance Inc

2013-07-09 Publication of SMT201300060B publication Critical patent/SMT201300060B/it

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Hydrogenated Pyridines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

SM201300060T 2009-04-23 2013-06-07 Composti diammidici aventi attivita' di antagonista al recettore muscarinico e di agonista al recettore beta 2 adrenergico SMT201300060B (it)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US17203909P	2009-04-23	2009-04-23
PCT/US2010/031356 WO2010123766A1 (en)	2009-04-23	2010-04-16	DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

Publications (1)

Publication Number	Publication Date
SMT201300060B true SMT201300060B (it)	2013-07-09

Family

ID=42272140

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SM20190168T SMT201900168T1 (it)	2009-04-23	2010-04-16	Composti diammidici aventi attivita' di antagonista al recettore muscarinico e di agonista al recettore beta 2 adrenergico
SM20170305T SMT201700305T1 (it)	2009-04-23	2010-04-16	Composti diammidici aventi attivita' di antagonista al recettore muscarinico e di agonista al recettore beta 2 adrenergico
SM201300060T SMT201300060B (it)	2009-04-23	2013-06-07	Composti diammidici aventi attivita' di antagonista al recettore muscarinico e di agonista al recettore beta 2 adrenergico

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
SM20190168T SMT201900168T1 (it)	2009-04-23	2010-04-16	Composti diammidici aventi attivita' di antagonista al recettore muscarinico e di agonista al recettore beta 2 adrenergico
SM20170305T SMT201700305T1 (it)	2009-04-23	2010-04-16	Composti diammidici aventi attivita' di antagonista al recettore muscarinico e di agonista al recettore beta 2 adrenergico

Country Status (31)

Country	Link
US (14)	US8138345B2 (it)
EP (3)	EP2599778B1 (it)
JP (3)	JP5671006B2 (it)
KR (1)	KR101769061B1 (it)
CN (2)	CN102405218B (it)
AR (1)	AR076412A1 (it)
AU (1)	AU2010239522B2 (it)
BR (1)	BRPI1014877B8 (it)
CA (1)	CA2758505C (it)
CL (1)	CL2011002637A1 (it)
CO (1)	CO6440584A2 (it)
CY (2)	CY1119008T1 (it)
DK (3)	DK2421849T3 (it)
ES (3)	ES2635358T3 (it)
HR (3)	HRP20130468T1 (it)
HU (2)	HUE035049T2 (it)
IL (1)	IL215554A (it)
LT (2)	LT3210981T (it)
MX (1)	MX2011011156A (it)
MY (1)	MY158339A (it)
NZ (1)	NZ595850A (it)
PL (3)	PL2599778T3 (it)
PT (3)	PT2599778T (it)
RU (2)	RU2676686C2 (it)
SG (1)	SG175330A1 (it)
SI (3)	SI3210981T1 (it)
SM (3)	SMT201900168T1 (it)
TR (1)	TR201903556T4 (it)
TW (2)	TWI570115B (it)
WO (1)	WO2010123766A1 (it)
ZA (1)	ZA201107743B (it)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010123766A1 (en)	2009-04-23	2010-10-28	Theravance, Inc.	DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
EP2386555A1 (en)	2010-05-13	2011-11-16	Almirall, S.A.	New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it)	2010-05-13	2011-11-14	De La Cruz Jose Antonio Freire	Piastra per la costruzione di carrelli per aeroplani
AR083115A1 (es) *	2010-09-30	2013-01-30	Theravance Inc	Sales oxalato cristalinas de un compuesto diamida
EP2718281B1 (en)	2011-06-10	2015-09-09	Chiesi Farmaceutici S.p.A.	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
HRP20151317T1 (hr)	2011-06-10	2016-01-01	Chiesi Farmaceutici S.P.A.	Spojevi koji pokazuju aktivnost prema antagonistima muskarinskog receptora i beta2 adrenergiäśnog receptora
EP2592078A1 (en)	2011-11-11	2013-05-15	Almirall, S.A.	New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
MX369311B (es)	2012-12-06	2019-11-05	Chiesi Farm Spa	Compuestos con actividad antagonista de los receptores muscarinicos y actividad agonista del receptor beta2 adrenergico.
RU2661877C2 (ru)	2012-12-06	2018-07-20	КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.	Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов
EP2934594B1 (en)	2012-12-18	2019-09-04	Almirall, S.A.	Cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities .
TWI643853B (zh)	2013-02-27	2018-12-11	阿爾米雷爾有限公司	同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh)	2013-07-25	2018-11-21	阿爾米雷爾有限公司	具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh)	2013-07-25	2015-05-16	Almirall Sa	含有ｍａｂａ化合物和皮質類固醇之組合
CN104030933A (zh) *	2014-05-16	2014-09-10	烟台恒迪克能源科技有限公司	一种β-异烷醇基氨基戊酸环己胺的合成方法
TW201617343A (zh)	2014-09-26	2016-05-16	阿爾米雷爾有限公司	具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
TWI703138B (zh)	2015-02-12	2020-09-01	義大利商吉斯藥品公司	具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
CN107074816B (zh) *	2015-03-27	2020-07-17	四川海思科制药有限公司	一种杂环衍生物及其制备方法和在医药上的用途
WO2016180348A1 (zh) *	2015-05-14	2016-11-17	四川海思科制药有限公司	具有β2受体激动及M受体拮抗活性的含氮杂螺环衍生物及其在医药上的用途
TW201704211A (zh) *	2015-05-14	2017-02-01	Sichuan Haisco Pharmaceutical Co Ltd	具有β２受體激動及Ｍ受體拮抗活性的聯苯衍生物及其在醫藥上的用途
AR104828A1 (es)	2015-06-01	2017-08-16	Chiesi Farm Spa	COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
EP3383867B1 (en)	2015-12-03	2021-04-14	Chiesi Farmaceutici S.p.A.	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP3406606A4 (en) *	2016-01-22	2019-06-26	Sichuan Haisco Pharmaceutical Co., Ltd.	HETEROCYCLIC NITROGEN AMIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHRAMACEUTICAL APPLICATION
WO2018011090A1 (en)	2016-07-13	2018-01-18	Chiesi Farmaceutici S.P.A.	Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
US11447485B2 (en)	2016-12-14	2022-09-20	Beijing Showby Pharmaceutical Co., Ltd.	Class of bifunctional compounds with quanternary ammonium salt structure
EP3625232B1 (en)	2017-05-19	2021-06-23	Council of Scientific and Industrial Research	Substituted methanopyrido [2, 1-a]isoindolones as machr modulators for treating various associated pathophysiological conditions and process for preparation thereof
US11484531B2 (en)	2018-08-30	2022-11-01	Theravance Biopharma R&D Ip, Llc	Methods for treating chronic obstructive pulmonary disease
CN117924216A (zh) *	2024-01-12	2024-04-26	王叔和生物医药(武汉)有限公司	一种1-哌啶丙酸的合成方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6541669B1 (en) *	1998-06-08	2003-04-01	Theravance, Inc.	β2-adrenergic receptor agonists
UA73543C2 (uk)	1999-12-07	2005-08-15	Тераванс, Інк.	Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
AU783095B2 (en) *	1999-12-07	2005-09-22	Theravance Biopharma R&D Ip, Llc	Carbamate derivatives having muscarinic receptor antagonist activity
US6858596B2 (en)	2000-08-05	2005-02-22	Smithkline Beecham Corporation	Formulation containing anti-inflammatory androstane derivative
AU7576001A (en)	2000-08-05	2002-02-18	Glaxo Group Ltd	6.alpha., 9.alpha.-difluoro-17.alpha.-`(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent
US6759398B2 (en)	2000-08-05	2004-07-06	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative
US6750210B2 (en)	2000-08-05	2004-06-15	Smithkline Beecham Corporation	Formulation containing novel anti-inflammatory androstane derivative
UA77656C2 (en)	2001-04-07	2007-01-15	Glaxo Group Ltd	S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US7151671B2 (en) *	2001-12-04	2006-12-19	Tokyo R & D Co., Ltd.	Power supply
CN101239970B (zh) *	2003-02-14	2011-07-20	施万制药	联苯衍生物
PE20040950A1 (es) *	2003-02-14	2005-01-01	Theravance Inc	DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
ES2289691T3 (es)	2004-01-22	2008-02-01	Pfizer, Inc.	Derivados de sulfonamida para el tratamiento de enfermedades.
US7320990B2 (en) *	2004-02-13	2008-01-22	Theravance, Inc.	Crystalline form of a biphenyl compound
WO2005092861A1 (en)	2004-03-11	2005-10-06	Pfizer Limited	Quinolinone derivatives pharmaceutical compositions containing them and their use
TWI341836B (en)	2004-03-11	2011-05-11	Theravance Inc	Biphenyl compounds useful as muscarinic receptor antagonists
US7307076B2 (en)	2004-05-13	2007-12-11	Boehringer Ingelheim International Gmbh	Beta agonists for the treatment of respiratory diseases
TWI374883B (en) *	2004-08-16	2012-10-21	Theravance Inc	Crystalline form of a biphenyl compound
EP1778626A1 (en) *	2004-08-16	2007-05-02	Theravance, Inc.	Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
EP1833822A2 (en) *	2004-08-16	2007-09-19	Theravance, Inc.	Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
CA2641706C (en)	2006-02-08	2014-12-23	Fuji Oil Company, Limited	Edible products with low content of saturated and trans unsaturated fats
GB0602778D0 (en) *	2006-02-10	2006-03-22	Glaxo Group Ltd	Novel compound
TW200811105A (en) *	2006-04-25	2008-03-01	Theravance Inc	Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200811104A (en) *	2006-04-25	2008-03-01	Theravance Inc	Crystalline forms of a dimethylphenyl compound
WO2008096129A1 (en)	2007-02-07	2008-08-14	Argenta Discovery Ltd	Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
KR20110050459A (ko)	2008-07-25	2011-05-13	비타이 파마슈티컬즈, 인코포레이티드	11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제
WO2010123766A1 (en)	2009-04-23	2010-10-28	Theravance, Inc.	DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

2010
- 2010-04-16 WO PCT/US2010/031356 patent/WO2010123766A1/en not_active Ceased
- 2010-04-16 CN CN201080017581.XA patent/CN102405218B/zh not_active Expired - Fee Related
- 2010-04-16 CA CA2758505A patent/CA2758505C/en not_active Expired - Fee Related
- 2010-04-16 TR TR2019/03556T patent/TR201903556T4/tr unknown
- 2010-04-16 SI SI201031866T patent/SI3210981T1/sl unknown
- 2010-04-16 RU RU2015101032A patent/RU2676686C2/ru active
- 2010-04-16 SM SM20190168T patent/SMT201900168T1/it unknown
- 2010-04-16 HU HUE13151470A patent/HUE035049T2/en unknown
- 2010-04-16 SI SI201031498T patent/SI2599778T1/sl unknown
- 2010-04-16 SM SM20170305T patent/SMT201700305T1/it unknown
- 2010-04-16 PT PT131514705T patent/PT2599778T/pt unknown
- 2010-04-16 PT PT17164740T patent/PT3210981T/pt unknown
- 2010-04-16 PL PL13151470T patent/PL2599778T3/pl unknown
- 2010-04-16 AU AU2010239522A patent/AU2010239522B2/en not_active Ceased
- 2010-04-16 HU HUE17164740A patent/HUE042975T2/hu unknown
- 2010-04-16 CN CN201410175377.0A patent/CN103936716B/zh not_active Expired - Fee Related
- 2010-04-16 PT PT107150583T patent/PT2421849E/pt unknown
- 2010-04-16 LT LTEP17164740.7T patent/LT3210981T/lt unknown
- 2010-04-16 BR BRPI1014877A patent/BRPI1014877B8/pt not_active IP Right Cessation
- 2010-04-16 US US12/761,532 patent/US8138345B2/en not_active Expired - Fee Related
- 2010-04-16 KR KR1020117027797A patent/KR101769061B1/ko not_active Expired - Fee Related
- 2010-04-16 PL PL10715058T patent/PL2421849T3/pl unknown
- 2010-04-16 JP JP2012507275A patent/JP5671006B2/ja not_active Expired - Fee Related
- 2010-04-16 DK DK10715058.3T patent/DK2421849T3/da active
- 2010-04-16 LT LTEP13151470.5T patent/LT2599778T/lt unknown
- 2010-04-16 RU RU2011147374/04A patent/RU2543716C2/ru active
- 2010-04-16 DK DK13151470.5T patent/DK2599778T3/en active
- 2010-04-16 EP EP13151470.5A patent/EP2599778B1/en active Active
- 2010-04-16 EP EP10715058A patent/EP2421849B1/en active Active
- 2010-04-16 ES ES13151470.5T patent/ES2635358T3/es active Active
- 2010-04-16 ES ES10715058T patent/ES2417339T3/es active Active
- 2010-04-16 NZ NZ595850A patent/NZ595850A/xx not_active IP Right Cessation
- 2010-04-16 SI SI201030228T patent/SI2421849T1/sl unknown
- 2010-04-16 PL PL17164740T patent/PL3210981T3/pl unknown
- 2010-04-16 EP EP17164740.7A patent/EP3210981B1/en active Active
- 2010-04-16 HR HRP20130468AT patent/HRP20130468T1/hr unknown
- 2010-04-16 MX MX2011011156A patent/MX2011011156A/es active IP Right Grant
- 2010-04-16 DK DK17164740.7T patent/DK3210981T3/en active
- 2010-04-16 ES ES17164740T patent/ES2715965T3/es active Active
- 2010-04-16 MY MYPI2011004779A patent/MY158339A/en unknown
- 2010-04-16 SG SG2011077765A patent/SG175330A1/en unknown
- 2010-04-23 TW TW104129981A patent/TWI570115B/zh not_active IP Right Cessation
- 2010-04-23 AR ARP100101379A patent/AR076412A1/es active IP Right Grant
- 2010-04-23 TW TW099112926A patent/TWI513693B/zh not_active IP Right Cessation
2011
- 2011-10-05 IL IL215554A patent/IL215554A/en active IP Right Grant
- 2011-10-19 CO CO11139777A patent/CO6440584A2/es active IP Right Grant
- 2011-10-21 CL CL2011002637A patent/CL2011002637A1/es unknown
- 2011-10-21 ZA ZA2011/07743A patent/ZA201107743B/en unknown
2012
- 2012-02-08 US US13/369,109 patent/US8551978B2/en not_active Expired - Fee Related
2013
- 2013-06-07 SM SM201300060T patent/SMT201300060B/it unknown
- 2013-08-12 US US13/964,484 patent/US8816088B2/en not_active Expired - Fee Related
2014
- 2014-07-10 US US14/327,853 patent/US9000173B2/en not_active Expired - Fee Related
- 2014-08-15 JP JP2014165381A patent/JP5965440B2/ja not_active Expired - Fee Related
2015
- 2015-03-04 US US14/638,171 patent/US9394275B2/en not_active Expired - Fee Related
- 2015-05-22 JP JP2015104157A patent/JP2015147807A/ja active Pending
2016
- 2016-06-13 US US15/180,165 patent/US9572802B2/en not_active Expired - Fee Related
- 2016-12-15 US US15/379,673 patent/US9682957B2/en not_active Expired - Fee Related
2017
- 2017-04-26 US US15/497,446 patent/US9771350B2/en not_active Expired - Fee Related
- 2017-05-09 CY CY20171100498T patent/CY1119008T1/el unknown
- 2017-06-26 HR HRP20170960TT patent/HRP20170960T1/hr unknown
- 2017-08-18 US US15/680,323 patent/US9975875B2/en active Active
2018
- 2018-04-23 US US15/959,549 patent/US10138220B1/en not_active Expired - Fee Related
- 2018-10-15 US US16/159,829 patent/US10358433B2/en not_active Expired - Fee Related
2019
- 2019-02-28 CY CY20191100250T patent/CY1121601T1/el unknown
- 2019-03-04 HR HRP20190417TT patent/HRP20190417T1/hr unknown
- 2019-06-07 US US16/434,220 patent/US10590107B2/en not_active Expired - Fee Related
2020
- 2020-01-28 US US16/774,024 patent/US10836744B2/en not_active Expired - Fee Related
- 2020-10-08 US US17/065,689 patent/US20210024493A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HK1165799A1 (en)	2012-10-12
EP2421849A1 (en)	2012-02-29
US20190300504A1 (en)	2019-10-03
PL2421849T3 (pl)	2013-08-30
BRPI1014877B8 (pt)	2021-05-25
PT2599778T (pt)	2017-06-06
JP5671006B2 (ja)	2015-02-18
CN102405218A (zh)	2012-04-04
PL3210981T3 (pl)	2019-06-28
US10836744B2 (en)	2020-11-17
US20160361304A1 (en)	2016-12-15
US20170362200A1 (en)	2017-12-21
CA2758505A1 (en)	2010-10-28
US20130331364A1 (en)	2013-12-12
IL215554A0 (en)	2011-12-29
HUE042975T2 (hu)	2019-07-29
EP2599778B1 (en)	2017-04-12
LT2599778T (lt)	2017-08-25
RU2676686C2 (ru)	2019-01-10
BRPI1014877A8 (pt)	2018-03-13
DK2421849T3 (da)	2013-07-01
ES2417339T3 (es)	2013-08-07
US20130137665A1 (en)	2013-05-30
HRP20130468T1 (en)	2013-06-30
AU2010239522A1 (en)	2011-11-10
CN103936716B (zh)	2016-09-07
US20210024493A1 (en)	2021-01-28
BRPI1014877A2 (pt)	2016-04-12
JP2014210816A (ja)	2014-11-13
HUE035049T2 (en)	2018-05-02
US9682957B2 (en)	2017-06-20
CA2758505C (en)	2017-03-07
SG175330A1 (en)	2011-11-28
WO2010123766A1 (en)	2010-10-28
IL215554A (en)	2014-08-31
JP2012524783A (ja)	2012-10-18
US9000173B2 (en)	2015-04-07
RU2011147374A (ru)	2013-05-27
US20100273755A1 (en)	2010-10-28
BRPI1014877B1 (pt)	2020-11-10
RU2543716C2 (ru)	2015-03-10
AU2010239522B2 (en)	2015-07-02
ES2635358T3 (es)	2017-10-03
RU2015101032A (ru)	2015-06-27
EP3210981B1 (en)	2019-01-02
US10138220B1 (en)	2018-11-27
US20190047984A1 (en)	2019-02-14
SMT201900168T1 (it)	2019-05-10
TW201041866A (en)	2010-12-01
US20170226082A1 (en)	2017-08-10
NZ595850A (en)	2013-05-31
EP2599778A1 (en)	2013-06-05
DK2599778T3 (en)	2017-06-26
PT2421849E (pt)	2013-05-27
US8138345B2 (en)	2012-03-20
US9394275B2 (en)	2016-07-19
US8551978B2 (en)	2013-10-08
CY1119008T1 (el)	2018-01-10
MX2011011156A (es)	2011-11-04
SI2421849T1 (sl)	2013-07-31
SI2599778T1 (sl)	2017-08-31
CN102405218B (zh)	2014-06-04
HRP20190417T1 (hr)	2019-04-19
US10590107B2 (en)	2020-03-17
PL2599778T3 (pl)	2018-01-31
PT3210981T (pt)	2019-04-01
US10358433B2 (en)	2019-07-23
CY1121601T1 (el)	2020-05-29
CN103936716A (zh)	2014-07-23
SMT201700305T1 (it)	2017-09-07
KR101769061B1 (ko)	2017-08-17
ES2715965T3 (es)	2019-06-07
MY158339A (en)	2016-09-30
TWI513693B (zh)	2015-12-21
JP2015147807A (ja)	2015-08-20
RU2015101032A3 (it)	2018-07-30
SI3210981T1 (sl)	2019-05-31
US9975875B2 (en)	2018-05-22
US20200165223A1 (en)	2020-05-28
DK3210981T3 (en)	2019-04-01
TW201546057A (zh)	2015-12-16
TR201903556T4 (tr)	2019-04-22
TWI570115B (zh)	2017-02-11
HRP20170960T1 (hr)	2017-09-22
CO6440584A2 (es)	2012-05-15
CL2011002637A1 (es)	2012-04-27
EP3210981A1 (en)	2017-08-30
US9771350B2 (en)	2017-09-26
US8816088B2 (en)	2014-08-26
US9572802B2 (en)	2017-02-21
US20150274697A1 (en)	2015-10-01
JP5965440B2 (ja)	2016-08-03
KR20110138292A (ko)	2011-12-26
US20140323733A1 (en)	2014-10-30
US20170096412A1 (en)	2017-04-06
LT3210981T (lt)	2019-04-10
AR076412A1 (es)	2011-06-08
EP2421849B1 (en)	2013-04-03
ZA201107743B (en)	2012-06-27

Publication	Publication Date	Title
SMT201300060B (it)	2013-07-09	Composti diammidici aventi attivita' di antagonista al recettore muscarinico e di agonista al recettore beta 2 adrenergico
MY155212A (en)	2015-09-30	Quaternary ammonium salt compounds
HRP20120129T8 (en)	2012-04-30	Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
EA201101398A1 (ru)	2012-04-30	Замещенные пиперидины в качестве антагонистов ccr3
BR112015020152A2 (pt)	2017-07-18	derivados de sais de 2-amino-1-hidroxietil-8-hidroxiquinolin-2(1h)-ona tendo tanto atividade de agonista de receptor adrenérgico beta2 quanto atividade de antagonista de receptor muscarínico m3
PA8774201A1 (es)	2009-06-23	Antagonista del receptor
MX2009010515A (es)	2009-10-19	Antagonistas del receptor opioide periferico y usos de los mismos.
MY148703A (en)	2013-05-31	Polycyclic cinnamide derivatives
MX390264B (es)	2025-03-20	Antagonistas d2, metodos de sintesis y metodos de uso.
MX2018015087A (es)	2023-01-31	Antagonistas de receptores de opiaceos perifericos y usos de los mismos.
BRPI0607015A2 (pt)	2009-12-01	composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
CO6140054A2 (es)	2010-03-19	Compuestos de dialquilfenilo con actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarinico
BRPI0512058A (pt)	2008-02-06	composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
NO20091464L (no)	2009-07-06	Heterocykliske forbindelser anvendelige som anaboliske midler for buskapsdyr
GB0607954D0 (en)	2006-05-31	Organic compounds
UY32460A (es)	2010-09-30	Derivados de ciclopropilamida '983"
CO6280492A2 (es)	2011-05-20	Tienopirimidinas hidrosustituidas como antagonistas de receptor -1 de hormona concentradora de melanina no basicos
EP2249833A4 (en)	2011-03-09	PROGRUGS OF CGRP RECEPTOR ANTAGONISTS
NZ600266A (en)	2014-06-27	Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
MX2010012421A (es)	2011-03-25	5-[5-[2-(3,5-bis(trifluormetil)fenil)-2-metilpropanoilmetilamino] -4-(4-fluoro-2-metilfenil)]-2-piridinil-2-alquil-prolinamida como antagosnistas del receptor de neurocinina 1.
BRPI0821611A8 (pt)	2016-12-13	Derivado de 3-carboxipropil-aminotetralina e compostos relacionados como antagonistas do receptor opióide mu
ATE525360T1 (de)	2011-10-15	Neuartige imidazolinylmethyl-aryl-sulfonamide
BRPI0907495A2 (pt)	2019-02-26	sulfonamidas de imidazolinilmetil arila
CY1114205T1 (el)	2016-08-31	ΕΝΩΣΕΙΣ ΔΙΑΜΙΔΙΩΝ ΠΟΥ ΕΧΟΥΝ ΔΡΑΣΗ ΑΝΤΑΓΩΝΙΣΤΗ ΜΟΥΣΚΑΡΙΝΙΚΟΥ ΥΠΟΔΟΧΕΑ ΚΑΙ ΑΓΩΝΙΣΤΗ β2 ΑΔΡΕΝΕΡΓΙΚΟΥ ΥΠΟΔΟΧΕΑ
NZ710361A (en)	2020-05-29	Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1h)-one derivatives having both β2 adrenergic receptor agonist and m3 muscarinic receptor antagonist activities